Flag of the European Union EU Clinical Trials Register Help

Clinical trials for acute myeloid leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    514 result(s) found for: acute myeloid leukemia. Displaying page 1 of 26.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000526-37 Sponsor Protocol Number: SAIL Start Date*: 2014-08-18
    Sponsor Name:GSO Global Clinical Research B.V.
    Full Title: An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination with the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Relapsed Or Refractory A...
    Medical condition: Patients with relapsed/refractory Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    19.1 100000004864 10000886 Acute myeloid leukemia LLT
    19.1 100000004864 10066638 Acute myeloid leukemia progression LLT
    19.1 100000004864 10028557 Myeloid leukemia, acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001543-94 Sponsor Protocol Number: AML2020 Start Date*: 2020-12-15
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Tagraxofusp in Patients with CD123+ or with Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia.
    Medical condition: Acute Myeloid Leukemia CD123 + or with BPDCN immunophenotype
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006852-37 Sponsor Protocol Number: CPKC412A2301 Start Date*: 2008-07-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase III randomized, double-blind study of induction(daunorubicin/cytarabine)and consolidation (high dose cytarabine) chemotherapy + midostaurin (PKC412) or placebo in newly diagnosed patients <...
    Medical condition: newly diagnosed FLT3 mutated acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) CZ (Completed) NL (Completed) SK (Completed) HU (Completed) BE (Completed) IT (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001777-19 Sponsor Protocol Number: HOVON 81 AML Start Date*: 2006-12-07
    Sponsor Name:HOVON foundation
    Full Title: A Phase II multicenter study to assess the tolerability and efficacy of the addition of Bevacizumab to standard induction therapy in AML and high risk MDS above 60 years.
    Medical condition: Acute myeloid leukaemia (AML), AML FAB M0-M2 or M4-M7; diagnosis with refractory anemia with excess of blasts (RAEB) or refractory anemia with excess of blasts in transformation (RAEB-T) with an IP...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000273-35 Sponsor Protocol Number: 2/2007/U/Sper Start Date*: 2007-03-22
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A Phase II, Open-Label, Multi-centre, 2-part study to assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia AML ...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024291 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017347-33 Sponsor Protocol Number: Clofarabine Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy
    Medical condition: Acute myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10000880 Acute myeloid leukaemia PT
    12.1 10000880 Acute myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005934-20 Sponsor Protocol Number: ALLO-WT1/IPC2011-006 Start Date*: 2013-06-12
    Sponsor Name:Institut Paoli-Calmettes
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009015 Chronic myeloid leukemia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004950-25 Sponsor Protocol Number: D-00272-CT2014001 Start Date*: 2008-01-06
    Sponsor Name:Cell Medica Ltd
    Full Title: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
    Medical condition: Acute Myeloid Leukaemia and Chronic Myeloid Leukaemia in adults.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000334-19 Sponsor Protocol Number: 702 Start Date*: 2012-08-09
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
    Full Title: Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML)
    Medical condition: Untreated patients aged 60> years with Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001594-93 Sponsor Protocol Number: IPH2102-201 Start Date*: 2013-05-15
    Sponsor Name:Innate Pharma
    Full Title: Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly patients with Acute Myeloid Leukemia (AML) in First Complete Remission
    Medical condition: Acute Myeloid Leukemia in Elderly patients in First Complete Remission
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006515-28 Sponsor Protocol Number: ASST_FARM_2021TMO_FT14 Start Date*: 2022-06-07
    Sponsor Name:AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA
    Full Title: Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML...
    Medical condition: Acute Myeloid Leukemia (AML) patients (=40 <65years)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003103-12 Sponsor Protocol Number: AML-CG2008 Start Date*: 2009-03-10
    Sponsor Name:Hospital of the University of Munich
    Full Title: A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy ...
    Medical condition: Adult patients (≥18 years) with newly-diagnosed acute myeloid leukemia (AML) - except acute promyelocytic leukemia (APL) and t(15;17)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004517-17 Sponsor Protocol Number: CGX-635-AML-204 Start Date*: 2006-11-29
    Sponsor Name:Stragen France
    Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML)
    Medical condition: Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003421-28 Sponsor Protocol Number: TUD-HINKL1-059 Start Date*: 2014-07-10
    Sponsor Name:Technische Universität Dreden
    Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia
    Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002986-30 Sponsor Protocol Number: CLBH589B2116 Start Date*: 2010-01-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase Ib, open-label, multi-center dose-finding study of oral panobinostat (LBH589) in combination with ara-C and mitoxantrone as salvage therapy for refractory or relapsed acute myeloid leukemia
    Medical condition: refractory or relapsed acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002094-18 Sponsor Protocol Number: REL-AML001/2017 Start Date*: 2018-05-18
    Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: Prospective evaluation of a continuation therapy with Midostaurin in adult patients with core-binding factor leukemia and integrated genetic analysis: a multi-center phase II study
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000238-37 Sponsor Protocol Number: VUHEM-MRD-2013 Start Date*: 2013-05-28
    Sponsor Name:VU University medical center
    Full Title: Treatment guided by detection of Minimal Residual Disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia
    Medical condition: Minimal residual disease after allogeneic stem cell transplantation in Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018418-53 Sponsor Protocol Number: CSTI571A2110 Start Date*: 2010-06-01
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia...
    Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009015 Chronic myeloid leukemia LLT
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000664-16 Sponsor Protocol Number: FLATauto Start Date*: 2008-02-26
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: Clinical phase II trial to evaluate the safety and efficacy of treosulfan combined with cytarabine and fludarabine prior to autologous haematopoietic stem cell transplantation in elderly patients w...
    Medical condition: elderly patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024291 Leukaemias acute myeloid HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005321-63 Sponsor Protocol Number: DSC/05/2357/15 Start Date*: 2006-03-13
    Sponsor Name:ITALFARMACO
    Full Title: Multicentre, open label, uncontrolled, pilot, phase II study of oral ITF2357 in subjects with acute myeloid leukemia refractory/resistant and/or not suitable for any alternative therapy
    Medical condition: Acute myeloid leukemia AML (any French-American-British [FAB] type with the exception of M3 subtype, acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024291 Leukaemias acute myeloid HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:58:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA